Biosimilars deliver dramatic reductions in drug costs—and the Inflation Reduction Act is supposed to encourage their uptake. But lower prices mean lower reimbursement, disincentivizing providers. PRECISIONvalue expert Amy Martin explains how in this 2-minute video.
